In the United States breast cancer is the second most common cancer diagnosed in women. Throughout a woman’s lifetime there is 1 in 8 chance that she will develop breast cancer. My research, using breast cancer cell lines, will consist of both in-vitro and in-vivo experiments investigating the effects of immunoadjuvant nanoparticles (gold nanoparticles (GNPs) + Anti-CD40) in priming the abscopal effect during radiotherapy. The abscopal effect is an effect whereby treating one tumor can lead to regression of cancer at distant untreated sites (e.g cancer metastasis). GNPs have been shown to enhance radiotherapy. While Anti-CD40, is an antibody that is responsible for an anti-tumor immune response that can boost the abscopal effect. The completed research could avail the development of nanoparticle-aided radio-immunotherapy, with potential impact in curative treatment of breast cancer patients with metastatic disease.
